Key Insights

Highlights

Treatment Research

7 treatments under study, led by Doxorubicin Hydrochloride

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01639521Phase 2WithdrawnPrimary

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Doxorubicin Hydrochloride1
  • Methotrexate1
  • Cisplatin1
  • Pegfilgrastim1
  • Gemcitabine Hydrochloride1

Active Sponsors

  • National Cancer Institute (NCI)1
  • University of Southern California1

Top Investigators

Related Conditions

  • Localized Transitional Cell Cancer Of The Renal Pelvis And Ureter1
  • Recurrent Bladder Cancer1
  • Urethral Cancer Associated With Invasive Bladder Cancer1
  • Ureter Cancer1
  • Regional Transitional Cell Cancer Of The Renal Pelvis And Ureter1

Activity Timeline